Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system - PubMed

Affiliations

• PMID: 9674860
• DOI: 10.1038/sj.bmt.1701257

Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system

S D Rowley et al. Bone Marrow Transplant. 1998 Jun.

Abstract

The CD34 antigen is expressed by human hematopoietic progenitor and stem cells. These cells are capable of reconstituting marrow function after marrow-ablative chemo-radiotherapy. Several different technologies have been developed for the separation of CD34+ cells from bone marrow or peripheral blood stem cell (PBSC) components. We used an immunomagnetic separation technique to enrich CD34+ cells from PBSC components in anticipation of autologous transplantation for patients with B lymphoid malignancies. Twenty-nine patients enrolled on this study and received mobilization chemotherapy followed by G-CSF. Of these, 21 achieved a peripheral blood CD34+ cell level of at least 2.0 x 10(4)/l required by protocol for separation of the stem cell components. A median of three components per patient was collected for processing. The average CD34+ cell concentration in the components after apheresis was 1.0 +/- 1.2%. After the CD34+ cell selection, the enriched components contained 0.6 +/- 0.6% of the starting nucleated cells. The recovery of CD34+ cells, however, averaged 58.4 +/- 19.2% of the starting cell number, with a purity of 90.8 +/- 6.5%. Overall depletion of CD34- cells was 99.96 +/- 0.06%. Nineteen patients were treated with marrow-ablative conditioning regimens and received an average of 6.2 +/- 2.0 x 10(6) CD34+ cells/kg body weight. These patients recovered to an ANC >0.5 x 10(9)/l at a median of 11 days (range 8-14), and platelet transfusion independence at a median of 9 days (range 5-13). Four patients died of transplant-related complications or relapse before 100 days after transplantation. No patient required infusion of unseparated cells because of failure of sustained bone marrow function. These data demonstrate that peripheral blood-derived CD34+ cells enriched by use of an immunomagnetic separation technique are capable of rapid engraftment after autologous transplantation.

Similar articles

• CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.

  Kasow KA, Sims-Poston L, Eldridge P, Hale GA. Kasow KA, et al. Biol Blood Marrow Transplant. 2007 May;13(5):608-14. doi: 10.1016/j.bbmt.2007.01.074. Epub 2007 Mar 23. Biol Blood Marrow Transplant. 2007. PMID: 17448921

• Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.

  Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS. Cao TM, et al. Cancer. 2001 Jun 15;91(12):2205-13. Cancer. 2001. PMID: 11413507

• Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.

  Leong CF, Habsah A, Teh HS, Goh KY, Fadilah SA, Cheong SK. Leong CF, et al. Malays J Pathol. 2008 Jun;30(1):31-6. Malays J Pathol. 2008. PMID: 19108409

• Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.

  Watanabe T, Kawano Y, Watanabe A, Takaue Y. Watanabe T, et al. Haematologica. 1999 Feb;84(2):167-76. Haematologica. 1999. PMID: 10091416 Review.

• Peripheral blood progenitor cells for autologous transplant in children.

  Madero L, Villa M, Benito A, Gonzalez M, Diaz MA. Madero L, et al. Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S8-10. Bone Marrow Transplant. 1998. PMID: 9630316 Review.

Cited by

• Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.

  Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Nash RA, et al. Biol Blood Marrow Transplant. 2003 Sep;9(9):583-91. doi: 10.1016/s1083-8791(03)00228-3. Biol Blood Marrow Transplant. 2003. PMID: 14506660 Free PMC article. Clinical Trial.

• Evolution of Gene Therapy, Historical Perspective.

  Malech HL, Garabedian EK, Hsieh MM. Malech HL, et al. Hematol Oncol Clin North Am. 2022 Aug;36(4):627-645. doi: 10.1016/j.hoc.2022.05.001. Epub 2022 Jun 27. Hematol Oncol Clin North Am. 2022. PMID: 35773053 Free PMC article. Review.

• Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.

  De Rosa L, Anghel G, Pandolfi A, Riccardi M, Amodeo R, Majolino I. De Rosa L, et al. Int J Hematol. 2004 Jan;79(1):85-91. doi: 10.1007/BF02983539. Int J Hematol. 2004. PMID: 14979484

• High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

  McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE. McSweeney PA, et al. Blood. 2002 Sep 1;100(5):1602-10. Blood. 2002. PMID: 12176878 Free PMC article. Clinical Trial.

• The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.

  Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI. Holloman JP, et al. Am J Stem Cells. 2013 Jun 30;2(2):95-107. Print 2013. Am J Stem Cells. 2013. PMID: 23862098 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database